In vitro and ex vivo methods predict the enhanced lung residence time of liposomal ciprofloxacin formulations for nebulisation

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 86, Issue 1, 2014, Pages 83-89

  Ong, Hui Xin ^a,b   Benaouda, Faiza ^c   Traini, Daniela ^a,b   Cipolla, David ^d   Gonda, Igor ^d   Bebawy, Mary ^e   Forbes, Ben ^c   Young, Paul M ^a,b  

^a WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d ARADIGM CORPORATION   (United States)

^e UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Calu 3; Ciprofloxacin; Isolated perfused lung; Liposomes; Pulmonary model; Transport

Indexed keywords

CIPROFLOXACIN;

ANIMAL CELL; ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG DIFFUSION; DRUG FORMULATION; DRUG TRANSPORT; EX VIVO STUDY; IN VITRO STUDY; IN VIVO STUDY; LUNG; MALE; NEBULIZATION; NONHUMAN; PREDICTION; RAT; SLOW DRUG RELEASE; SUSTAINED RELEASE FORMULATION;

CALU-3; CIPROFLOXACIN; ISOLATED PERFUSED LUNG; LIPOSOMES; PULMONARY MODEL; TRANSPORT;

ABSORPTION; ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; CIPROFLOXACIN; DELAYED-ACTION PREPARATIONS; HUMANS; LIPOSOMES; LUNG; MALE; MEMBRANES, ARTIFICIAL; MODELS, BIOLOGICAL; NEBULIZERS AND VAPORIZERS; PERFUSION; PREDICTIVE VALUE OF TESTS; RATS; RATS, WISTAR; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84896700415     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2013.06.024     Document Type: Article

References (42)

1. D.E. Geller Aerosol antibiotics in cystic fibrosis Respir. Care 54 2009 658 670
2. T.S. Murray, M. Egan, and B.I. Kazmierczak Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients Curr. Opin. Pediatr. 19 2007 83
3. D. Wood, and A. Smyth Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis Review 2009
4. P. Bruinenberg, J.D. Blanchard, D.C. Cipolla, F. Dayton, S. Mudumba, and I. Gonda Inhaled liposomal ciprofloxain: once a day management of respiratory infections R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, S.J. Farr, Respiratory Drug Delivery 2010 Davis Healthcare International Publishing River Grove, Orlando, Florida
5. J. Gubernator, Z. Drulis-Kawa, A. Dorotkiewicz-Jach, W. Doroszkiewicz, and A. Kozubek In vitro antimicrobial activity of liposomes containing ciprofloxacin, meropenem and gentamicin against gram-negative clinical bacterial strains Lett. Drug Des. Discovery 4 2007 297 304
6. I.A.J.M. Bakker-Woudenberg, T. Marian, L. Guo, P. Working, and J.W. Mouton Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats Antimicrob. Agents Chemother. 45 2001 1487 1492
7. Z. Drulis-Kawa, and A. Dorotkiewicz-Jach Liposomes as delivery systems for antibiotics Int. J. Pharm. 387 2010 187 198
8. J.T. McConville, N. Patel, N. Ditchburn, M.J. Tobyn, J.N. Staniforth, and P. Woodcock Use of a novel modified TSI for the evaluation of controlled-release aerosol formulations. I Drug Dev. Ind. Pharm. 26 2000 1191 1198
9. R.O. Salama, D. Traini, H.K. Chan, and P.M. Young Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols Eur. J. Pharm. Biopharm. 70 2008 145 152
10. I. Gonda Drugs administered directly into the respiratory tract: modeling of the duration of effective drug levels J. Pharm. Sci. 77 1988 340 346
11. H.X. Ong, D. Traini, and P.M. Young Pharmaceutical applications of the Calu-3 lung epithelia cell line Exp. Opin. Drug Deliv. 2013 1 16
12. R. Salama, D. Traini, H.K. Chan, and P.M. Young Recent advances in controlled release pulmonary therapy Curr. Drug Deliv. 6 2009 404 414
13. P. Saarinen-Savolainen, T. Järvinen, H. Taipale, and A. Urtti Method for evaluating drug release from liposomes in sink conditions Int. J. Pharm. 159 1997 27 33
14. M. Beck-Broichsitter, J. Gauss, T. Gessler, W. Seeger, T. Kissel, and T. Schmehl Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles J. Aerosol Med. Pulm. Drug Deliv. 23 2010 47 57
15. M. Nagarsenker, and V. Londhe Preparation and evaluation of a liposomal formulation of sodium cromoglicate Int. J. Pharm. 251 2003 49 56
16. J. Widdicombe Regulation of the depth and composition of airway surface liquid J. Anat. 201 2002 313 318
17. H. Fischer, and J.H. Widdicombe Mechanisms of acid and base secretion by the airway epithelium J. Membr. Biol. 211 2006 139 150
18. H.X. Ong, D. Traini, M. Bebawy, and P.M. Young Epithelial profiling of antibiotic controlled release respiratory formulations Pharm. Res. 2011 1 12
19. M. Haghi, R. Salama, D. Traini, M. Bebawy, and P.M. Young Modification of disodium cromoglycate passage across lung epithelium in vitro via incorporation into polymeric microparticles AAPS J. 2011 1 8
20. H.X. Ong, D. Traini, D. Cipolla, I. Gonda, M. Bebawy, H. Agus, and P.M. Young Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia Pharm. Res. 2012 1 12
21. A. Tronde, C. Bosquillon, and B. Forbes The isolated perfused lung for drug absorption studies C. Ehrhardt, K.J. Kim, Drug Absorption Studies - In situ, In vitro and In silico Models 2008 Springer New York 135 163
22. M. Sakagami In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery Adv. Drug Deliv. Rev. 58 2006 1030 1060
23. D. Yim, J.D. Blanchard, S. Mudumba, S. Eastman, K. Manda, T. Redelmeier, and S.J. Farr The development of inhaled liposome-encapsulated ciprofloxcin to treat cystic fibrosis R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, S.J. Farr, Respiratory Drug Delivery X 2006 Davis Healthcare Int'l Publishing LCC River Grove, Boca Raton, Florida 425 428
24. M.S. Webb, N.L. Boman, D.J. Wiseman, D. Saxon, K. Sutton, K.F. Wong, P. Logan, and M.J. Hope Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation Antimicrob. Agents Chemother. 42 1998 45
25. M. Haghi, P.M. Young, D. Traini, R. Jaiswal, J. Gong, and M. Bebawy Time- and passage-dependent characteristics of a Calu-3 respiratory epithelial cell model Drug Dev. Ind. Pharm. 36 2010 1207 1214
26. C. Grainger, L. Greenwell, G. Martin, and B. Forbes The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa Eur. J. Pharm. Biopharm. 71 2009 318 324
27. C.I. Grainger, L.L. Greenwell, D.J. Lockley, G.P. Martin, B. Forbes, C.I. Grainger, L.L. Greenwell, D.J. Lockley, G.P. Martin, and B. Forbes Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier Pharm. Res. 23 2006 1482 1490
28. M. Madlova, C. Bosquillon, D. Asker, P. Dolezal, and B. Forbes In-vitro respiratory drug absorption models possess nominal functional P-glycoprotein activity J. Pharm. Pharmacol. 61 2009 293 301
29. K. Hutchison, A.L. Po, and I. Gonda Numerical analysis of approximations to the planar diffusion equation J. Pharm. Pharmacol. 33 1981 46P
30. J. Siepmann, and N.A. Peppas Higuchi equation: derivation, applications, use and misuse Int. J. Pharm. 418 2011 6 12
31. D.C. Cipolla, F. Dayton, S. Fulzale, E. Gabatan, S. Mudumba, D. Yim, H. Wu, and R. Zwilinski Inhaled liposomal ciprofloxacin: in vitro properties and aerosol performance R.N. Dalby, P.R. Byron, J. Peart, J.D. Suman, S.J. Farr, P.M. Young, Respiratory Drug Delivery 2010 Davis Healthcare Int'l Publishing River Grove, Orlando Florida 409 414
32. N.R. Mathias, J. Timoszyk, P.I. Stetsko, J.R. Megill, R.L. Smith, and D.A. Wall Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro-in vivo correlation to predict lung absorption in rats J. Drug Target. 10 2002 31 40
33. A. Tronde, B. Nordén, A.B. Jeppsson, P. Brunmark, E. Nilsson, H. Lennernäs, and U.H. Bengtsson Drug absorption from the isolated perfused rat lung-correlations with drug physicochemical properties and epithelial permeability J. Drug Target. 11 2003 61 74
34. F. Manford, A. Tronde, A.B. Jeppsson, N. Patel, F. Johansson, and B. Forbes Drug permeability in 16HBE14o-airway cell layers correlates with absorption from the isolated perfused rat lung Eur. J. Pharm. Sci. 26 2005 414 420
35. A. Tronde, B. Nordén, H. Marchner, A.K. Wendel, H. Lennernäs, and U.H. Bengtsson Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure, Äìabsorption relationships and physicochemical profiling of inhaled drugs J. Pharm. Sci. 92 2003 1216 1233
36. M.E. Cavet, M. West, and N.L. Simmons Transepithelial transport of the fluoroquinolone ciprofloxacin by human airway epithelial Calu-3 cells Antimicrob. Agents Chemother. 41 1997 2693 2698
37. C. Bosquillon Drug transporters in the lung, do they play a role in the biopharmaceutics of inhaled drugs? J. Pharm. Sci. 99 2010 2240 2255
38. H.X. Ong, D. Traini, M. Bebawy, and P.M. Young Ciprofloxacin is actively transported across bronchial lung epithelial cells using a Calu-3 air interface cell model Antimicrob. Agents Chemother. 57 2013 2535 2540
39. B. Forbes, and C. Ehrhardt Human respiratory epithelial cell culture for drug delivery applications Eur. J. Pharm. Biopharm. 60 2005 193 205
40. F. Komada, S. Iwakawa, N. Yamamoto, H. Sakakibara, and K. Okumura Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung J. Pharm. Sci. 83 1994 863 867
41. B.L. Laube, G.W. Benedict, and A.S. Dobs Time to peak insulin level, relative bioavailability, and effect of site of deposition of nebulized insulin in patients with noninsulin-dependent diabetes mellitus J. Aerosol Med. 11 1998 153 173
42. S.-A. Cryan, N. Sivadas, and L. Garcia-Contreras In vivo animal models for drug delivery across the lung mucosal barrier Adv. Drug Deliv. Rev. 59 2007 1133 1151